Human umbilical cord mesenchymal stem cell secretome (hUC-MSC secretome)

The Human umbilical cord mesenchymal stem cell (hUC-MSC) paracrine milieu refers to the comprehensive collection of bioactive molecules and extracellular vesicles secreted by these cells to modulate their biological environment. Rather than acting as a single molecular target, this milieu functions as a multi-component therapeutic system that influences diverse immune cells—including T-cells, B-cells, and macrophages—and various tissue-resident cells to suppress inflammation and stimulate repair. Key components such as transforming growth factor-beta (TGF-beta), interleukin-10 (IL-10), and indoleamine 2,3-dioxygenase (IDO) are instrumental in inducing immune tolerance and preventing tissue damage in autoimmune and inflammatory contexts. In clinical research, the hUC-MSC secretome is being explored as a cell-free alternative to traditional stem cell therapy, offering potential advantages in stability, dosage control, and reduced immunogenicity. It plays a significant role in treating conditions like graft-versus-host disease, liver cirrhosis, and myocardial infarction by promoting angiogenesis and inhibiting apoptosis. Because it represents a complex biological system rather than a discrete receptor or enzyme, it is classified as a therapeutic agent or modality rather than a conventional drug target (Source: PubMed, PMC7270071; Nature Scientific Reports, 2021).

Other names

hUC-MSC paracrine milieuUmbilical cord-derived mesenchymal stem cell conditioned mediumhUC-MSC-derived extracellular vesicleshUC-MSC-derived exosomesUmbilical cord MSC secretome

The hUC-MSC paracrine milieu modulates the immune system and promotes tissue repair by secreting a variety of bioactive factors such as TGF-beta, IL-10, PGE2, and IDO, which inhibit effector T-cell proliferation and promote regulatory T-cell formation. Additionally, extracellular vesicles (exosomes) within the milieu deliver microRNAs and proteins to recipient cells, triggering regenerative signaling pathways and reducing oxidative stress (Source: Frontiers in Immunology, 2020; Wang et al., 2022, 'Mesenchymal Stem Cell-Derived Secretome').